 |
|
|
Average Annual Rates of Invasive and In Situ Endometrial Cancer
|
|
Placebo
|
Tamoxifen
|
| Type of Event |
No. of Events |
Rate per 1,000 Women |
No. of Events |
Rate per 1,000 Women |
Risk Ratio |
95% Confidence Interval |
| Invasive Cancer |
15 |
0.91 |
36 |
2.30 |
2.53 |
1.35–4.97 |
| Age ≤49 |
8 |
1.09 |
9 |
1.32 |
1.21 |
0.41–3.60 |
| Age ≥50 |
7 |
0.76 |
27 |
3.05 |
4.01 |
1.70–10.90 |
|
In Situ Cancer |
3 |
0.18 |
1 |
0.06 |
0.35 |
0.01–4.38 |
|
No. = number.
|
|
Table adapted from Fisher et al. Tamoxifen for Prevention of Breast Cancer:
Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Journal of the National Cancer Institute 90 (18): 1371–1388, 1998.
|
|
|
|
